马来西亚羽毛球公开赛3日落幕，中国队进入3个项目的决赛：混双决赛中郑思维/黄雅琼登顶，陈雨菲获得女单银牌，郑雨/张殊贤在女双决赛中1∶2惜败印尼组合拉哈尤/西蒂，同样获得银牌。         Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness. 
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source. 
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations. 
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。决赛中以21∶13、21∶18横扫泰国混双强档德查波尔/沙西丽后，“雅思”组合本赛季的连胜场次上升至25场，两人联手连续拿下亚锦赛、泰国公开赛、印尼大师赛、印尼公开赛和马来西亚公开赛5个冠军。泰国媒体“Sanook”赛后称，决赛中的混双世界头号组合郑思维/黄雅琼几乎不可阻挡，他们比以往任何时候打得都好。从双方交战数据来看，斩获9胜2负的“雅思”组合继续扩大领先优势。

B | 女单决赛也是中泰选手隔网相争，今年第6次打入巡回赛决赛的中国队一姐陈雨菲1∶2不敌因达农，在无缘本赛季第二冠的同时，也让27岁的泰国名将结束长达两年的世界羽联巡回赛冠军荒。值得一提的是，陈雨菲的本赛季首冠来自不久前的印尼大师赛，当时她在决赛中击败的正是因达农。本次女单冠军战是陈雨菲与因达农的第18次交手，此役过后，陈雨菲在交手记录上依然占据上风（15胜3负）。

C |

从印尼大师赛的3金1银到印尼公开赛的2金2银，再到大马公开赛的1金2银，中国队最近3站巡回赛成绩呈现下滑趋势，男队表现与女队差距较大。以本次马来西亚站为例，中国队男单和男双均止步1/4决赛。

D |

Current article:http://fcb14t.yaoyaotoutuanmieshaideizun.buzz/news/20260826_9193.html

Published on:05:45:36